Related references
Note: Only part of the references are listed.Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?
Simon K. Winn et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib
Guillaume Bollee et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
A Preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
Tejas V. Patel et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
The case - Progressive hypertension and proteinuria on anti-angiogenic therapy
Jagdeep S. Obhrai et al.
KIDNEY INTERNATIONAL (2008)
Glomerular disease related to anti-VEGF therapy
M. Barry Stokes et al.
KIDNEY INTERNATIONAL (2008)
VEGF inhibition and renal thrombotic microangiopathy
Vera Eremina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome
E. Kapiteijn et al.
ANNALS OF ONCOLOGY (2007)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)